Clinical, molecular and immune analysis of dabrafenib and trametinib in metastatic melanoma patients that progressed on BRAF inhibitor monotherapy: a phase II clinical trial: CombiDT in BRAF inhibitor refractory melanoma patients

IMPORTANCE: Combined treatment with dabrafenib and trametinib (CombiDT) achieves clinical responses in only ~15% of BRAF inhibitor (BRAFi)-refractory metastatic melanoma patients, in contrast to the high activity observed in BRAFi-naïve patients. Identifying correlates of response and mechanisms of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Chen, Guo, McQuade, Jennifer L., Panka, David J., Hudgens, Courtney W., Amin-Mansour, Ali, Mu, Xinmeng Jasmine, Bahl, Samira, Jane-Valbuena, Judit, Wani, Khalida M., Reuben, Alexandre, Creasy, Caitlyn A., Jiang, Hong, Cooper, Zachary A., Roszik, Jason, Bassett, Roland L., Joon, Aron Y., Simpson, Lauren M., Mouton, Rosalind D., Glitza, Isabella C., Patel, Sapna P., Hwu, Wen-Jen, Amaria, Rodabe N., Diab, Adi, Hwu, Patrick, Lazar, Alexander J., Wargo, Jennifer A., Garraway, Levi A., Tetzlaff, Michael T., Sullivan, Ryan J., Kim, Kevin B., Davies, Michael A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4982774/
https://ncbi.nlm.nih.gov/pubmed/27124486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2016.0509
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados